Sacituzumab govitecan: Additional Phase I/II data

Interim data from 19 patients with relapsed or refractory metastatic urothelial cancer in the Phase II portion of an open-label, U.S. Phase I/II trial showed

Read the full 256 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE